394 related articles for article (PubMed ID: 22751544)
1. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.
Dolton MJ; Ray JE; Chen SC; Ng K; Pont LG; McLachlan AJ
Antimicrob Agents Chemother; 2012 Sep; 56(9):4793-9. PubMed ID: 22751544
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.
Dolton MJ; Ray JE; Chen SC; Ng K; Pont L; McLachlan AJ
Antimicrob Agents Chemother; 2012 Nov; 56(11):5503-10. PubMed ID: 22890761
[TBL] [Abstract][Full Text] [Related]
3. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole concentrations and outcome of invasive fungal infections.
Miyakis S; van Hal SJ; Ray J; Marriott D
Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
Howard A; Hoffman J; Sheth A
Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration.
Purkins L; Wood N; Ghahramani P; Love ER; Eve MD; Fielding A
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):37-44. PubMed ID: 14616412
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and clinical use of voriconazole.
Thompson GR; Lewis JS
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):83-94. PubMed ID: 19947892
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole in clinical practice.
Mikulska M; Novelli A; Aversa F; Cesaro S; de Rosa FG; Girmenia C; Micozzi A; Sanguinetti M; Viscoli C
J Chemother; 2012 Dec; 24(6):311-27. PubMed ID: 23174096
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole. UK 109496.
Drugs R D; 1999 Feb; 1(2):187-8. PubMed ID: 10566023
[No Abstract] [Full Text] [Related]
13. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
15. [Level of evidence for therapeutic drug monitoring of voriconazole].
Hulin A; Dailly E; Le Guellec C;
Therapie; 2011; 66(2):109-14. PubMed ID: 21635857
[TBL] [Abstract][Full Text] [Related]
16. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.
Michael C; Bierbach U; Frenzel K; Lange T; Basara N; Niederwieser D; Mauz-Körholz C; Preiss R
Antimicrob Agents Chemother; 2010 Aug; 54(8):3225-32. PubMed ID: 20547816
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole : a review of its use in the management of invasive fungal infections.
Scott LJ; Simpson D
Drugs; 2007; 67(2):269-98. PubMed ID: 17284090
[TBL] [Abstract][Full Text] [Related]
19. Review of the safety and efficacy of voriconazole.
Hoffman HL; Rathbun RC
Expert Opin Investig Drugs; 2002 Mar; 11(3):409-29. PubMed ID: 11866669
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]